NasdaqCM - Nasdaq Real Time Price USD

Aethlon Medical, Inc. (AEMD)

0.3693

-0.0097

(-2.56%)

At close: December 11 at 4:00:02 PM EST

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 8 days ago

BNRG

ICON

VIOT
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The company has made significant strides in moving its clinical activities forward over the past few weeks. The company has enrolled the first two patients in its oncology trial

Zacks Small Cap Research 27 days ago

AEMD
-2.56%
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.According to a recent article in Bio

Newsfile 27 days ago

AEMD
-2.56%
Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...

Aethlon Medical Inc (AEMD) advances its international oncology trials while managing financial challenges and leveraging tax benefits.

GuruFocus.com 28 days ago

AEMD
-2.56%
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.

PR Newswire 28 days ago

AEMD
-2.56%
Innovative Medical Technology Advances with First Patient Enrollments

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article on Investorideas.comhttps://www.invest

Newsfile 29 days ago

AEMD
-2.56%
Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer

The first patient was enrolled at the Cancer Clinical Trials Unit at CALHN, Royal Adelaide Hospital.

Medical Device Network 30 days ago

AEMD
-2.56%
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The

PR Newswire 30 days ago

AEMD
-2.56%
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.

PR Newswire last month

AEMD
-2.56%
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire last month

VOXR

BVAXF

CIA
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR

NASDAQ:AEMD Anthony Krause: Hello and welcome to Virtual Investor Conferences. My name is Anthony Krause, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we're very pleased you have joined us for our next live presentation from Aethlon Medical. Their session will be moderated by Marla Marin, senior Analyst at Zacks Small Cap Research. Please note that you can submit

Zacks Small Cap Research last month

AEMD
-2.56%
Aethlon Medical Inc (AEMD) Q1 2025 Earnings Call Highlights: Strategic Cost Management and ...

Aethlon Medical Inc (AEMD) reports a significant reduction in operating expenses and advances in clinical trials, despite ongoing financial challenges.

GuruFocus.com 2 months ago

AEMD
-2.56%
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET.

PR Newswire 2 months ago

AEMD
-2.56%
AEMD: Positive Takeaways from Life Science Investor Forum Presentation

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT AEMD basket oncology trial, patient enrollment process We participated in a discussion with Aethlon Medical (NASDAQ:AEMD) Interim Chief Executive Officer and Chief Financial Officer James Frakes and Chief Medical Officer Steven LaRosa, MD, last week at the Life Science Investor Forum. We present our takeaways in this note. The company’s

Zacks Small Cap Research 2 months ago

AEMD
-2.56%
Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c

GlobeNewswire 2 months ago

VGZ

AEMD
-2.56%
IMRN
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held September 19th are now available for online viewing. This event was co-sponsored by Zacks Small-Cap Research. REGISTER NOW AT: https://bit.ly/3TuSFdy The company presentations will be available 24/

GlobeNewswire 2 months ago

BVAXF

EVAX

PLX
Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 19, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon's Hemopurifier® is a clinical stage immunother

Newsfile 2 months ago

AEMD
-2.56%
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda®

PR Newswire 2 months ago

AEMD
-2.56%
Aethlon Medical to Present at Virtual Investor Conferences in September

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September:

PR Newswire 2 months ago

AEMD
-2.56%
Innovation Driving Cancer's Solid Tumors Market

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for the treatment of cancer and solid tumors featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024/b

Newsfile 2 months ago

AEMD
-2.56%

Performance Overview

Return	AEMD	S&P 500
YTD	-83.14%	+27.56%
1-Year	-81.72%	+32.14%
3-Year	-98.32%	+29.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aethlon Medical, Inc. (AEMD)

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Innovative Medical Technology Advances with First Patient Enrollments

Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, Interim CEO & CFO, and Steven LaRosa, MD, Chief Medical Officer, of Aethlon Medical Inc., with Marla Marin, Senior Analyst at Zacks SCR

Aethlon Medical Inc (AEMD) Q1 2025 Earnings Call Highlights: Strategic Cost Management and ...

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

AEMD: Positive Takeaways from Life Science Investor Forum Presentation

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Aethlon Medical to Present at Virtual Investor Conferences in September

Innovation Driving Cancer's Solid Tumors Market

Performance Overview